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Abstract Diabetes mellitus is a metabolic disease character-
ized by hyperglycemia due to defects in insulin secretion or its
action. Complications from long-term diabetes consist of nu-
merous biochemical, molecular, and functional tissue alter-
ations, including inflammation, oxidative stress, and neuro-
pathic pain. There is also a link between diabetes mellitus
and vascular dementia or Alzheimer’s disease. Hence, it is
important to treat diabetic complications using drugs which
do not aggravate symptoms induced by the disease itself.
Pregabalin is widely used for the treatment of diabetic neuro-
pathic pain, but little is known about its impact on cognition or
inflammation-related proteins in diabetic patients. Thus, this
study aimed to evaluate the effect of intraperitoneal (ip)
pregabalin on contextual memory and the expression of in-
flammatory state-related proteins in the brains of diabetic,
streptozotocin (STZ)-treated mice. STZ (200 mg/kg, ip) was
used to induce diabetes mellitus. To assess the impact of
pregabalin (10 mg/kg) on contextual memory, a passive
avoidance task was applied. Locomotor and exploratory ac-
tivities in pregabalin-treated diabetic mice were assessed by
using activity cages. Using Western blot analysis, the expres-
sion of cyclooxygenase-2 (COX-2), cytosolic prostaglandin E
synthase (cPGES), nuclear factor (erythroid-derived 2)-like 2
(Nrf2), nuclear factor-ĸB (NF-ĸB) p50 and p65, aryl
hydrocarbon receptor (AhR), as well as glucose transporter
type-4 (GLUT4) was assessed in mouse brains after
pregabalin treatment. Pregabalin did not aggravate STZ-
induced learning deficits in vivo or influence animals’ loco-
motor activity. We observed significantly lower expression of
COX-2, cPGES, and NF-κB p50 subunit, and higher expres-
sion of AhR and Nrf2 in the brains of pregabalin-treated mice
in comparison to STZ-treated controls, which suggested im-
munomodulatory and anti-inflammatory effects of pregabalin.
Antioxidant properties of pregabalin in the brains of diabetic
animals were also demonstrated. Pregabalin does not potenti-
ate STZ-induced cognitive decline, and it has antioxidant,
immunomodulatory, and anti-inflammatory properties in
mice. These results confirm the validity of its use in diabetic
patients.
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Introduction
Diabetes mellitus is one of the most prevalent chronic diseases
characterized by elevated blood glucose levels due to defects
in insulin secretion or its action.Metabolic impairments of this
disorder are a substantial cause of severe biochemical, molec-
ular, and functional complications in many organs of the body,
leading consequently to progressive damage to the whole or-
ganism (Baquer et al. 2009). The most prominent complica-
tions of long-term diabetes mellitus comprise cardiovascular
diseases, stroke, chronic kidney failure, inflammation, and
peripheral nerve injuries accompanied by neuropathic pain
episodes (Biessels et al. 2002; Biessels and Gispen 2005;
Kumar et al. 2016).
Much less recognized than diabetic neuropathic pain
(DNP) and a not fully addressed complication of diabetes
mellitus is cognitive dysfunction, which represents a serious
medical problem in elderly patients with diabetes (Datusalia
and Sharma 2014). Available studies indicate that diabetes
mellitus is a risk factor for vascular type dementia (Zuloaga
et al. 2015), but in recent years, a strong link has been shown
between Alzheimer’s disease (AD), the most common form of
dementia, and diabetes mellitus (Gasparini et al. 2002;
Biessels et al. 2006; Pasquier et al. 2006; Baquer et al. 2009;
Datusalia and Sharma 2014; Solmaz et al. 2015), indicating
that impairments of insulin secretion or action can seriously
influence not only the proper functioning of peripheral tissues,
but also brain functions, being a cause of cognitive decline in
diabetic patients (Pasquier et al. 2006).
The management of diabetes-induced complications com-
prises multiple therapeutic strategies. Among these, much
attention is paid to the approaches which aim to achieve
relief of DNP (Schreiber et al. 2015). This pathological con-
dition affects more than 25 % of diabetic patients (Tesfaye
et al. 2013), significantly worsening their quality of life
through a negative impact on sleep, mood, and everyday
functionality. In this respect, the use of analgesic adjuvants
(e.g., anticonvulsant drugs, antidepressant drugs) is regarded
as one of the therapeutic mainstreams in the pharmacother-
apy of DNP (Finnerup et al. 2015).
One second-generation antiepileptic drug, pregabalin, is a
ligand of the α2δ subunit of voltage-gated calcium channels
which has shown high clinical efficacy in the treatment of
DNP in humans (Finnerup et al. 2015; Zhang et al. 2015). It
has also attenuated tactile allodynia in mouse models of neu-
ropathic pain induced by streptozotocin (STZ) (Sałat et al.
2013a; Sałat and Sałat 2013), oxaliplatin (Sałat et al. 2014;
Sałat and Sałat 2015), as well as chronic constriction injury
(Sałat et al. 2015), and it is metabolically neutral (Sałat et al.
2013b), which combined validate the use of this drug as a
first-line option for the treatment of DNP (Tesfaye et al. 2013).
The available literature shows that the adverse effects of
pregabalin are mild, and generally, this drug is well tolerated
(Rosenstock et al. 2004; Tölle et al. 2008; Moon et al. 2010;
Toth 2014). The most frequently reported adverse effects of
pregabalin are related to its influence on the central nervous
system and these comprise dizziness, somnolence
(Rosenstock et al. 2004; Toth 2014), or the propensity for
abuse (Grosshans et al. 2013). Importantly, among these cen-
trally mediated actions, little is known about the impact of
pregabalin on cognition, brain glucose metabolism, or
diabetes-related brain tissue inflammation. Two available re-
search reports (Liliana et al. 2015; Javed et al. 2015) indicate
that this drug may have a lower rate of cognitive side effects
than other antiepileptic drugs, but these studies were not per-
formed in diabetes-related conditions.
Hence, the present study aimed to assess the effect of
pregabalin on cognition in STZ-treated mice. STZ is a
nitrosourea analog antitumor drug that induces diabetes by
killing β-pancreatic cells (Gao and Zheng 2014). Since the
development of STZ-induced diabetes in rodents is relatively
simple with a single injection, this model has been widely
used to study mechanisms of diabetes, diabetic peripheral
neuropathy, and DNP (Tanabe et al. 2008; Chauhan et al.
2012; Gao and Zheng 2014). Previously, it has shown that
not only the intracerebral application of STZ leads to memory
deficits (Blokland and Jolles 1993; Chen et al. 2013), but the
intraperitoneal (ip) administration of this drug can also induce
memory impairments (Cai et al. 2011; Davari et al. 2013;
Miao et al. 2015; Takizawa et al. 2013). Given this fact, it is
assumed that STZ can not only have a tremendous impact on
sensory nerves and pain sensitivity thresholds, but it can also
modulate various brain functions, including learning abilities
(Davari et al. 2013). Also, biochemical and molecular alter-
ations induced by impaired glucose metabolism can have a
tremendous impact on the body’s functioning (Baquer et al.
2009; Ola et al. 2012; Coleman et al. 2015; Kumar et al.
2016), including the brain functions (Biessels et al. 2002;
Gasparini et al. 2002; Baquer et al. 2009; King et al. 2015).
Consequently, as a part of our research, we also evaluated the
influence of STZ and pregabalin on the expression of the
following proteins in the mouse brain: cyclooxygenase-2
(COX-2), cytosolic prostaglandin E2 synthase (cPGES), nu-
clear factor (erythroid-derived 2)-like 2 (Nrf2), nuclear
factor-ĸB (NF-ĸB) p50 and p65, aryl hydrocarbon receptor
(AhR), and glucose transporter type-4 (GLUT4).
Materials and methods
Chemicals
Pregabalin was purchased from Tocris Bioscience (Germany).
For in vivo studies, it was dissolved in 0.9 % saline (Polfa
Kutno, Poland) and administered at a dose of 10 mg/kg by the
ip route 60 min before the locomotor activity test and the
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acquisition phase of the passive avoidance task. The dose of
pregabalin tested in the present study was chosen based on the
previous research (Sałat et al. 2013a) showing its significant
antiallodynic activity in STZ-induced DNP in mice. STZ
(Sigma-Aldrich, Poland) was dissolved in 0.1 N citrate buffer
(pH 4.5) and injected in a single ip dose of 200 mg/kg (for
details see the BInduction of diabetes and selection of diabetic
mice for further tests^ section).
Animals and housing conditions
Adult male Albino Swiss (CD-1) mice weighing between 18
and 22 g were used in this study. The animals were housed in
groups of 10 mice per cage at an ambient temperature of 22
±2 °C, under a light/dark (12:12) cycle. The animals had free
access to food and water before experiments. The ambient
temperature of the experimental room and humidity were kept
constant throughout the tests. For the behavioral test, the an-
imals were selected randomly. Each experimental group
consisted of seven to eight animals. The experiments were
performed between 8 AM and 2 PM. Immediately after the
in vivo assay, the animals were euthanized via cervical dislo-
cation. The procedures for animal maintenance and treatment
were approved by the Local Ethics Committee of the
Jagiellonian University in Krakow (ZI/862/2013).
In vivo part
Induction of diabetes and selection of diabetic mice for further
tests
Before the induction of diabetes, the mice were randomly
divided into two groups. The first received only a vehicle
(an equal volume of 0.1 N citrate buffer), while the latter
was injected with ip STZ dissolved in 0.1 N citrate buffer.
Blood glucose levels were measured 1 h before STZ injection
(referred to as Bpre-STZ^) and repeatedly 7, 14, and 21 days
after STZ injection. For this purpose, a blood glucose moni-
toring system (AccuChek Active, Roche, France) was applied.
Blood samples for the measurement of glucose concentration
were obtained from the mouse tail vein. The animals were
considered diabetic when their blood glucose concentration
exceeded 300 mg/dl (Tanabe et al. 2008) and only those mice
were used as diabetic mice in further tests.
Passive avoidance task
The learning abilities of diabetic mice and the effect of
pregabalin on cognition were investigated using a passive
avoidance task 21 days after STZ administration. For this
purpose, diabetic mice were first randomly divided into
pregabalin-treated or vehicle-treated groups (STZ +
pregabalin-treated group and STZ + vehicle-treated group,
respectively). The passive avoidance task was performed ac-
cording to a method previously described by Park et al.
(2012). The apparatus used in the test (Panlab Harvard
Apparatus, Spain) consisted of a large white-painted illumi-
nated compartment (26 × 26 × 34 cm) and a small black-
painted dark compartment (13×7.5×7.5 cm) separated from
each other by a guillotine gate. To assess the effect of
pregabalin and STZ on memory impairments, the animals
underwent two separate trials: an acquisition trial (condition-
ing phase) and a retention trial (testing phase). The latter was
conducted 24 h after the acquisition trial.
In the acquisition trial, the mouse was initially placed for
30 s in the light compartment (exploration period; guillotine
gate is closed). After this 30-s exploration period, the guillo-
tine door (5×5 cm) between the light and the dark compart-
ments was opened and the time elapsed before entering the
black chamber was recorded. As soon as the mouse entered
the dark compartment, the door was automatically closed and
an electrical shock (current intensity 0.2 mA, duration 2 s) was
delivered through the grid floor.
In the retention trial, the mice were placed again in the
illuminated, white compartment and the latency time between
door opening and entry into the dark compartment was record-
ed for each mouse. If the mouse did not enter the dark com-
partment within 180 s (cut off latency), it was concluded that it
had remembered the foot shock from the acquisition trial.
Better memory performance was indicated by longer latency
to enter in the black chamber in the test (retention) phase than
in the conditioning (acquisition) phase.
Activity monitoring
Activity monitoring was performed using activity cages
(40×40×31 cm) supplied with I.R. horizontal and vertical
beam emitters (Activity Cage 7441, Ugo Basile, Italy) con-
nected to a counter measuring the number of light-beam inter-
rupts. Before the test, the mice were habituated to the activity
cages for a period of 30 min. In this test, 60 min before the
experiment, the mice were pretreated with pregabalin. Then,
the animals were placed in the activity cages in a sound-
attenuated room. Software analysis enabled the measurement
of the following three types of behavior during the next
30 min at 3-min intervals: ambulations, rearing, and grooming
(the number of grooming bouts and the total duration of
grooming activity) (Cartmell et al. 2000; Kalueff and
Tuohimaa 2005).
Ex vivo part—Western blot for quantity of protein
expression
The brain tissues were collected and then homogenized on ice
using T-PER (Thermo Scientific, Waltham, MA, USA) buffer
with protease inhibitor cocktail set III (Calbiochem, Merck,
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Germany) and phosphatase inhibitors (Cayman Chemical,
Ann Arbor, MI, USA). Protein concentrations were deter-
mined using the Bradford reaction. Aliquots (20 μg) were
solubilized in a Laemmli buffer with 2 % mercaptoethanol
(BioRad, Hercules, CA, USA) and subjected to 10 % SDS-
polyacrylamide gel electrophoresis as described previously
(Gdula-Argasińska et al. 2015). We used primary antibodies:
anti-COX-2 (diluted 1:500), anti-cPGES (diluted 1:1000),
anti-Nrf2 (diluted 1:100), anti-AhR (diluted 1:500), and anti-
GAPDH (diluted 1:1000) (GeneTex Inc., Irvine, CA, USA),
as well as NF-ĸB p50, NF-ĸB p65 (Cayman Chemical), dilut-
ed 1:100 and anti-GLUT4 (Sigma-Aldrich, Saint Louis, MO,
USA), diluted 1:200 in Signal + for Western Blot (GeneTex).
The secondary antibody was EasyBlot anti-rabbit IgG (HRP)
diluted 1:1000 in Signal + for Western blot (GeneTex).
Proteins were detected using a Clarity Western ECL luminol
Substrate Western blotting detection kit (Bio-Rad). The inte-
grated optical density of the bands was quantified using a
ChemiDoc Camera with Image Lab software (Bio-Rad).
Data analysis
Data analysis of the results was carried out using GraphPad
Prism software (v. 5, USA). Numerical results from behavioral
tests are expressed as means ± standard error of the mean
(SEM). For the statistical analysis, one-way analysis of vari-
ance (ANOVA) was used, followed by Newman-Keuls post
hoc comparison or two-way repeated measures ANOVA,
followed by Bonferroni multiple comparison. In the ex vivo
part of this research, the values are presented as means±SD.
One-way ANOVA with Tukey’s or Scheffe’s post hoc tests
were performed to evaluated differences in protein expression.
P<0.05 was considered significant.
Results
Measurements of blood glucose level
As shown in Fig. 1, an overall effect of treatment was ob-
served (F[1,66]=956.95, P<0.0001) which resulted in hyper-
glycemia in STZ-treated mice. Time also affected the results
in a statistically significant manner (F[3,66] = 351.16,
P < 0.0001). Drug × time interaction was also significant
(F[3,66]=343.60, P<0.0001). For the first time, an elevated
blood glucose level was observed 7 days after STZ adminis-
tration. It was maintained during the following days (signifi-
cant at P<0.001 vs. normoglycemic control at each time-
point). On day 21, after STZ injection, 3 h after the last mea-
surement of blood glucose concentration, behavioral tests
were performed in all experimental groups.
Passive avoidance
In this fear-motivated task, the effect of pregabalin on STZ-
induced cognitive dysfunction was investigated. A significant
overall effect of treatment was observed (F[2,19] = 5.33,
P<0.05). Time also affected the results significantly (F[1,
19]=72.86, P<0.0001). Drug× time interaction was also sig-
nificant (F[2,19]=4.71, P<0.05). In the acquisition phase,
the step-through latency was similar in all experimental
groups. In the retention phase of this test in all tested groups,
prolongation of step-through latency was observed (Fig. 2).
However, the step-through latency of STZ-treated control
mice was significantly shorter compared to that of control
animals not treated with STZ (P< 0.01). In the retention
phase, the difference in the step-through latency between
STZ-treated control group and STZ + pregabalin-treated mice
was not statistically significant (Fig. 2).
Activity monitoring
Animals’ behavior was monitored by measuring ambulations,
rearing, and grooming activity. None of the treatments affect-
ed the number of ambulations (F[2,17] = 2.37, P > 0.05;
Fig. 3a), but time affected the results in a statistically signifi-
cant manner (F[9,153]=2.18, P<0.05). Drug× time interac-
tion was not significant (F[18,153]=1.20, P>0.05).
Treatment with STZ or pregabalin had no influence on the
number of rears (F[2,17]=0.05, P>0.05; Fig. 3b). Time did
not affect the results, either (F[9,153] = 1.81, P > 0.05).
Drug × time interaction was not significant (F[18,
153]=0.89, P>0.05).
Neither STZ, nor pregabalin affected the number of
grooming bouts (F[2,17]=3.137, P>0.05; Fig. 3c). In con-
trast to this, compared to non-diabetic controls, both treat-
ments significantly decreased the total duration of grooming
behavior (F[2,16] = 29.16, P<0.0001; Fig. 3d) by 55 and
90 %, respectively, for STZ + vehicle-treated and STZ +
pregabalin-treated groups.
Western blot for quantity of protein expression
COX-2 expression in the brains was lower in STZ + vehicle-
treated control and STZ + pregabalin-treated mice in compar-
ison to the non-diabetic controls (F[2,21] = 200.17,
P< 0.0001). Statistically significant (P< 0.05 vs. vehicle-
treated group and P<0.001 vs. STZ + vehicle-treated mice)
repression of this protein was observed in diabetic mice treat-
ed with pregabalin (Fig. 4a).We observed different expression
levels of cPGES in all experimental groups (F[2,21]=977.86,
P<0.0001). Statistically, the highest expression of cPGES
protein was observed in the brains of STZ + vehicle-treated
mice when compared to the STZ + pregabalin-treated group
(P<0.001). The level of this protein was higher in the brains
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of those groups, when compared to vehicle-treated mice
(P<0.05; Fig. 4b). Also, there was a significant difference in
Nrf2 expression in the three experimental groups (F[2,
21]=214.57, P<0.0001). In the brains of pregabalin-treated
diabetic animals, a statistically significant repression of Nrf2
was observed (P<0.05 vs. control and P<0.001 vs. STZ +
vehicle; Fig. 4c). The highest amount of Nrf2 was observed in
the brains of STZ + vehicle control mice, when compared to
control non-diabetic mice (P < 0.05) and the STZ +
pregabalin-treated group (P<0.001). NF-ĸB p50 expression
was significantly higher in the brains of STZ control animals
(two-fold), when compared to STZ + pregabalin-treated mice
(P < 0.001) and non-diabetic controls (P < 0.05) (F[2,
21] = 891.39, P<0.01; Fig. 4d). The expression of NF-ĸB
p65 remained unchanged in the brains of STZ control and
STZ + pregabalin-treated mice (Fig. 4e). Compared to the
vehicle-treated group, the expression of AhR was lower in
the brains of STZ controls (not significant). It was statistically
higher in STZ + pregabalin-treated mice compared to the
vehicle-treated group (P < 0.05) and STZ controls
(P<0.001) (F[2,21]=208.22, P<0.0001; Fig. 4f). After treat-
ment with pregabalin, a significant (P<0.001) repression of
GLUT4 was observed in mouse brains, when compared to
STZ-treated control animals (F[2,21] = 358.52, P<0.0001;
Fig. 4g).
Discussion
Long-term diabetes mellitus is a disease that not only impairs
the endocrine homeostasis of an organism, but also affects the
functioning of the central and peripheral nervous systems
(Biessels et al. 2002; King et al. 2015). The disease itself is
regarded as one of the risk factors for AD (Nguyen et al. 2014;
Ohara et al. 2011) and diabetes-induced cognitive decline,
accompanied by biochemical impairments within diabetic
brains, resembles that typical for AD (Court and Perry 1991;
Giacobini et al. 1989; Hoyer 2002a, b; Mao et al. 2014).
Hence, these cognitive deficits seem to be particularly trou-
blesome and serious, and therefore, it is important to treat
diabetic patients using drugs which do not aggravate these
potential pre-existing memory deficits.
In the present study, to induce diabetes, we used STZ as a
convenient and easy-to-use tool (Gao and Zheng 2014).When
treated with a single dose of STZ, most mice and rats become
hyperglycemic within several days, and after 2 to 3 weeks,
they exhibit behavioral signs of DNP (Tanabe et al. 2008;
Sałat et al. 2013a), i.e., tactile allodynia and thermal
hyperalgesia in response to mechanical and thermal stimuli,
respectively (Tanabe et al. 2008; Gao and Zheng 2014).
The duration of diabetes mellitus is thought to be one of the
key factors for rodent studies on DNP and its effective treat-
ment (Obrosova 2009), as well as diabetes-related cognitive
Fig. 1 Mean blood glucose
levels in vehicle-treated control
mice and STZ-treated mice
measured before STZ
administration (pre-STZ) and
then 7, 14, and 21 days after STZ
injection. Statistical analysis: two-
way repeated measures analysis
of variance (ANOVA), followed




Fig. 2 Effect of STZ and pregabalin on learning and memory in the
passive avoidance task. Results are shown as the mean step-through
latency (±SEM) in the acquisition phase (day 1) and in the retention
phase (day 2). Statistical analysis: two-way repeated measures analysis
of variance (ANOVA), followed by Bonferroni post hoc comparison.
Significance vs. vehicle-treated (non-diabetic) mice in the retention
phase: **P< 0.01
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deficits (Biessels and Gispen 2005). This is due to the fact that
both these diabetes-related complications share a common
etiology, i.e., neuropathy (Moriarty et al. 2016). Since the
main objective of the present research was to assess the impact
of pregabalin on learning and memory in conditions related to
DNP, this study was performed 3 weeks after STZ injection.
We chose this time-point for behavioral assays to keep testing
protocols in conditions as close as possible to our previous
studies on the antiallodynic and antihyperalgesic properties of
pregabalin in the DNP model (Sałat et al. 2013a).
Studies on the cognitive abilities of STZ-treated diabetic
rodents are based on several learning tasks (Biessels et al.
2002; Moriarty et al. 2016). To assess the effect of pregabalin
on learning and memory in diabetic mice, we used a passive
avoidance task. This fear-motivated test is a simple and rapid
cognitive task (Puzzo et al. 2014; Arias et al. 2015) which
evaluates long-term memory in rodents (Lee et al. 2015). It
enables the researcher to study a conditioned response to var-
ious contextual cues and, therefore, it is particularly useful to
investigate emotional memory and contextual memory (Lee
et al. 2015; Arias et al. 2015). Recently, a link has been found
between emotional and cognitive alterations, impaired contex-
tual fear conditioning, and diabetes-related conditions
(Hwang et al. 2010; Ikeda et al. 2015; Zuloaga et al. 2015).
Moreover, using the passive avoidance task, learned aspects of
defensive behavior and the involvement of different brain
structures in mechanisms of these types of memory (amygda-
la, hippocampus, respectively) can be studied (Puzzo et al.
2014; Lee et al. 2015; Arias et al. 2015). Another important
reason for using the passive avoidance task was that our pre-
vious experiments on pregabalin in the DNP model were per-
formed on albino mice, and this task is in fact one of the
easiest and most readily available screens to study cognition
in these mice. Albino mice tend to show significant impair-
ments in spatial navigation tasks due to visual impairments
(Puzzo et al. 2014); so, in contrast to other, more sophisticated
tools which evaluate spatial navigation, learning, and memory
(e.g., Morris water maze or radial-arm water maze), the pas-
sive avoidance task does not require C57BL/6J mice. In our
study, in the retention phase of the passive avoidance task, we
observed reduced step-through latency in the STZ-treated
control group compared to non-diabetic controls, which
Fig. 3 Effect of pregabalin on diabetic STZ-treated animals’ activity
measured as the number of ambulations (a), rears (b), and grooming
behavior (c, d). Data are expressed as mean ± SEM. Behaviors were
monitored over a 30-min time period. Statistical analysis: two-way
repeated measures analysis of variance (ANOVA), followed by
Bonferroni post hoc comparison (a, b) or one-way ANOVA, followed
by Newman-Keuls multiple comparison test (c, d). Significance vs.
vehicle-treated (non-diabetic) mice: ***P< 0.001, and vs. STZ-treated
control: ##P< 0.01
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confirmed the results of other authors showing that STZ-
induced diabetes had a deleterious effect on learning and
memory in numerous tasks (Biessels and Gispen 2005;
Datusalia and Sharma 2014), including fear conditioning tasks
(Zuloaga et al. 2015). Pregabalin did not aggravate learning
deficits of STZ-treated mice as compared to STZ controls. On
the other hand, pregabalin was not able to attenuate or reverse
STZ-induced memory impairments. A slight reduction in
step-through latency was observed in pregabalin-treated mice
compared to diabetic controls, but this difference was not sta-
tistically significant.
In order to properly interpret the results from the passive
avoidance task, i.e., to assess if the effects of STZ and
pregabalin observed in this test were not due to altered motor
skills, impaired exploratory behavior, or stress-related reac-
tions, animals’ activity was additionally monitored by mea-
suring ambulations, rearing, grooming bouts, and the total
duration of grooming activity (Cartmell et al. 2000; Kalueff
and Tuohimaa 2005). To achieve the most precise as possible
insight into these activities, ambulations and rearing were
measured at 3-min intervals, which strictly corresponded to
the duration of a single-passive avoidance trial. Compared to
non-diabetic controls, neither STZ, nor pregabalin influenced
the total number of ambulations or rearing, which indicates
that those treatments do not affect locomotor activity or ex-
ploratory behavior (Kalueff and Tuohimaa 2005). This is a
Fig. 4 The effect of STZ and pregabalin on COX-2 (a), cPGES (b), Nrf2
(c), NF-ĸB p50 (d), NF-ĸB p65 (e), AhR (f), and GLUT4 (g) protein
expression in mouse brains. Results are shown as fold changes of
control. Statistical analysis: one-way ANOVA, followed by Tukey’s or
Scheffe’s post-hoc test. Significance vs. non-diabetic vehicle-treated
mice: *P < 0.05; significance vs. STZ + vehicle-treated mice:
###P< 0.001
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particularly important information in reference to the observed
reduced step-through latency in STZ + vehicle-treated mice
and STZ + pregabalin-treated mice compared to
normoglycemic controls in the retention trial of the passive
avoidance task. Namely, it confirms that the effect of STZ or
pregabalin on fear-motivated learning was not masked by al-
tered locomotor activity or explorative behavior.
For a proper interpretation of the results obtained in the
passive avoidance task, several other factors should also be
considered. One of these is related to the anxiolytic properties
of the drug under testing. In fact, the observed reduction of
step-through latency in the retention trial of the passive avoid-
ance task might be explained in terms of cognitive decline, but
there is also a possibility that this effect might result from the
anxiolytic-like properties of the test drug. Since pregabalin has
anxiolytic properties (Toth 2014), as a next step, we decided to
assess if it influences grooming behavior. In rodents, self-
grooming behavior is a natural activity which is very sensitive
to stress and various procedures that are made on animals.
Concomitantly, it can be regarded as a spontaneous ritual be-
havior and a behavioral marker of animal welfare that appears
in low-stress conditions (Kalueff and Tuohimaa 2005). On the
other hand, under certain circumstances, grooming can also be
a marker of anxiety, and anxiety can lead to increased frequen-
cy or duration of grooming. Hence, a thorough analysis of this
behavior is regarded as a tool which is complementary to the
available mouse tests used to study anxiety-related behavior
(Kalueff and Tuohimaa 2005). For both these options (i.e.,
anxiolytic or anxiogenic), to differentiate between them, it is
extremely important to analyze qualitative characteristics of
grooming (Kalueff and Tuohimaa 2005). In our present study,
STZ and pregabalin did not affect the number of grooming
bouts; however, in the case of the STZ + pregabalin-treated
group, a trend for a reduction of this parameter could be noted.
Compared to the normoglycemic controls, the total duration of
grooming activity was significantly affected by both STZ and
pregabalin. Interestingly, there was also a significant differ-
ence between both STZ-treated groups. Previously, it had
been reported (Kalueff and Tuohimaa 2005) that the number
of bouts and, to a lesser extent, the duration of grooming may
not detect anxiety, if taken alone. Hence, as a part of the
analysis, we also carefully observed the qualitative features
of grooming behavior. Typically, sudden bursts of rapid and
very intense grooming activity with abnormal progression and
incomplete and interrupted bouts were noted in STZ-treated
controls but, notably, not in the non-diabetic controls. This
type of high-stress-related activity seen in STZ control was
almost unnoted in the STZ + pregabalin-treated group.
Taken together, this might indicate that this pattern of
grooming activity in STZ control was a manifestation of
anxiety-related behavior, and the effect of pregabalin on its
duration might be attributed to its potential anxiolytic proper-
ties. In previous studies (Kalueff and Tuohimaa 2005),
anxiolytic GABAergic drugs had been shown to decrease
grooming activity measures in the open field, and anxiolytic
agents reduced grooming duration and frequency in rats.
Summarizing, in view of the above results, this might be the
main limitation of the present in vivo study, as the observed
reduction of step-through latency in the retention phase of the
passive avoidance task seems to be strongly influenced by
anxiolytic properties of pregabalin.
The CNS plays an integral role in maintaining glucose
homeostasis by promoting hormone release and through in-
nervation of peripheral organs via sympathetic and parasym-
pathetic actions (Ren et al. 2015). Molecular mechanisms of
insulin action and its role in the brain are still not clearly
understood. The presence of insulin and its receptors in the
brain suggests a key role for insulin as a neuromodulator of
neurotransmitter of neuronal activity (Leloup et al. 1996).
Moreover, in the CNS, insulin affects feeding behavior and
body energy stores, as well as various aspects of memory and
cognition (Gray et al. 2014). Discrete brain areas express the
insulin-responsive glucose transporter GLUT4 (Leloup et al.
1996). The levels of expression of GLUT4 protein in the cer-
ebellum appear to respond to the level of circulating insulin
(Vannucci et al. 1998). In our study, we observed significant
repression of GLUT4 proteins in the pregabalin-treated dia-
betic mouse brains when compared to STZ-treated control
animals. This suggested that pregabalin influences the expres-
sion of glucose transporters in the mouse brain.
The STZ model of diabetes has also been widely studied to
understand mechanisms underlying DNP. Several etiological
factors have been identified, including oxidative stress and
inflammation (Gao and Zheng 2014). Also, the theory for
aging and the pathogenesis of cerebral dysfunction in diabetes
relates cell death to oxidative stress in strong association to
inflammation and in fact NF-κB signaling (Muriach et al.
2014). The pro-inflammatory NF-κB pathway has been re-
vealed as a key molecular system for pathologic induction of
brain inflammation, which translates over-nutrition and
resulting intracellular stress into central neuroendocrine and
neural dysregulations of energy, glucose, and cardiovascular
homeostasis (Cai and Liu 2012).
In our study, we observed significantly lower expression of
COX-2, cPGES, and NF-κB p50 subunit in the brains of dia-
betic mice treated with pregabalin in comparison to STZ-
treated control mice. Higher expression of the AhR receptor
was observed in the brains of STZ + pregabalin-treated mice.
Our results suggest an anti-inflammatory effect of pregabalin,
both at the lower COX-2 and cPGES brain expression and
also via inhibition of the NF-κB signaling by preventing p50
and p65 translocation to the nucleus.
AhR, as a nuclear factor, participates in NF-κB signaling
pathways regulating inflammation (Quintana and Sherr 2013).
In our study, expression of AhR was the highest and the ex-
pression of p50 was lower in the brains of pregabalin-treated
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mice when compared to STZ control animals. This probably
suggested transrepression of NF-ĸB by AhR. The results of
the study performed by Calikoglu et al. (2015) indicated anti-
edematous, anti-inflammatory, and neuroprotective effects of
pregabalin in an experimental head trauma model in rats. In
the work of Jang et al. (2012), in a mouse model of neuropa-
thy, pregabalin demonstrated immunomodulatory effects by
inhibiting NK cell activity and splenocyte proliferation. Ha
et al. (2011) indicated lower synthesis of caspase-3 and phos-
phorylated p38 MAPK and decreased proliferation of astro-
cytes in rats with spinal cord injury after administration of
pregabalin. Our study confirmed these immunomodulatory
actions of pregabalin in diabetic mice.
Brain inflammation may result from both acute injury and
the appearance of endogenous neurotoxic metabolites associ-
ated with neurodegenerative diseases. COX-2 expression in
the brain has been associatedwith pro-inflammatory activities,
but the evidence of a direct role of COX-2 in neurodegenera-
tive events is still controversial. The emerging role of COX-2
in behavioral and cognitive functions is still being discussed
(Minghetti 2004). Prostaglandin E2 is among the most impor-
tant mediators involved in neuroinflammatory processes (de
Oliveira et al. 2008).
Neurochemical targets to reduce brain inflammation in-
clude NF-ĸB signaling, cyclooxygenase enzymes, Nrf2 tran-
scription factors, angiotensin AT1, and sigma-1 receptors. The
search for more selective drugs acting on these targets is of
great interest (Jarrott and Williams 2015). The brain is very
sensitive to changes in redox status; thus, maintaining redox
homeostasis in the brain is critical for the prevention of oxi-
dative damage. Nrf2 is a redox-sensitive, ligand-activated
transcription factor that plays a critical role in cellular defenses
against oxidative and electrophilic stress. Nrf2 activation has
been shown to mitigate a number of pathologic mechanisms
associated with AD, Parkinson’s disease, amyotrophic lateral
sclerosis, Huntington’s disease, and multiple sclerosis (Wang
et al. 2014). In our study, we observed higher expression of
Nrf2 proteins in the brain of STZ-treated control mice when
compared to STZ + pregabalin-treated mice. This suggested
the repression of this protein and the reduction of oxidative
stress in the brains of diabetic animals after pregabalin
treatment.
Concluding, in this research, we have demonstrated that
pregabalin does not aggravate memory deficits induced by
STZ injection. Moreover, this drug has anti-inflammatory
and antioxidant properties in STZ-treated mice. The results
obtained in the present study might be relevant when consid-
ering the increasing use of pregabalin for epileptic and non-
epileptic medical indications.
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